Halozyme Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Helen I. Torley
- Full Time Employees
- 423
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 12390 El Camino Real San Diego CA United States of America 92130
- IPO Date
- Mar 16, 2004
- CIK
- 0001159036
- Website
- halozyme.com
- Similar Companies
- Business
- Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biopharmaceutical company that develops and commercializes proprietary enzyme-based drug delivery technologies and oncology therapies. The company's core ENHANZE platform, powered by the patented recombinant human hyaluronidase enzyme (rHuPH20), facilitates subcutaneous delivery of injectable biologics including monoclonal antibodies, other therapeutic molecules, small molecules, and fluids; it supports partnered products such as DARZALEX FASPRO (subcutaneous), Phesgo, VYVGART Hytrulo, Tecentriq Subcutaneous, and Ocrevus Subcutaneous across oncology, immunology, and neurology indications. Halozyme also commercializes XYosted, a testosterone replacement therapy via an auto-injector, and previously marketed Hylenex and Tlando prior to license terminations. Founded in 1998 and headquartered in San Diego, California, Halozyme operates primarily in the United States with global partnerships enabling international reach through collaborators in pharmaceutical and biotechnology sectors targeting diabetes, cancer, dermatology, autoimmune diseases, and rare disorders. In recent developments, Halozyme completed the acquisition of Elektrofi in late 2025 for up to $900 million, integrating the Hypercon microparticle technology to expand subcutaneous delivery options and strengthen partnerships with big pharma; the deal includes $750 million upfront plus milestones tied to product approvals, with royalties expected from 2030. The company expanded its argenx collaboration with an upfront payment and milestones, secured a new global agreement with Merus N.V. for ENHANZE in bispecific antibodies, and gained regulatory approvals for Roche's Tecentriq and Ocrevus subcutaneous formulations; partners nominated five new targets for clinical advancement in 2024, contributing to record 2024 revenue exceeding $1 billion. These initiatives underscore Halozyme's focus on organic pipeline growth, strategic alliances, and share repurchases up to $250 million.
Company News
Halozyme to Participate at Upcoming Investor Conferences
Halozyme: The Market May Be Underpricing The Second Growth Wave
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Canada Pension Plan Investment Board Purchases Shares of 132,600 Halozyme Therapeutics, Inc. $HALO
Freestone Grove Partners LP Acquires New Stake in Halozyme Therapeutics, Inc. $HALO
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice
5 Value Stocks to Buy Right Now as Inflation Remains Sticky
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
5 Biotech Stocks Worth Adding to Your Portfolio Now
NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run?
Halozyme Therapeutics: Running Through 2027
Allworth Financial LP Acquires New Shares in Halozyme Therapeutics, Inc. $HALO
HALO Stock Rises 36% in a Month: Here's What You Should Know
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
Halozyme Appoints Dannielle Appelhans to its Board of Directors
Sagtec Officially Launches HALO AI and Secures US$3 Million Purchase Order for 1,500 AI Food-Serving Robots from Dubai Distributor
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
Is Halozyme Therapeutics (HALO) Stock Outpacing Its Medical Peers This Year?
Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up
Halozyme Therapeutics Q2 Earnings Call Highlights